|N-(4-(3-丙烯酰胺基苯甲酰胺基)苯基)-6-(1H-吡唑-3-基)吡啶-2-甲酰胺|CsnPharm

CAS No.: 2227368-54-7

Jh-X-119-01 is a novel potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor.

规格	价格	促销价格	库存	数量

400-920-2911

加入购物车大规格询价

产品咨询

400-920-2911

纯度 & 质量文件批次:

生物活性

描述Jh-X-119-01 is a highly potent and selective covalent inhibitor of IRAK1. JH-X-119-01 inhibited IRAK1 biochemically with an IC50 of 9.3 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 µM, and showed exceptional Kinome selectivity with off-target inhibition of only two kinases, YSK4 and MEK3. Intact protein MS labeling studies confirmed that JH-X-119-01 irreversibly labels IRAK1 at C302. Jh-X-119-01 exhibited cytotoxic activity at single digit micromolar concentrations in a panel of WM (Waldenström's macroglobulinemia), DLBCL (Diffused Large B-cell Lymphoma), and lymphoma cell lines expressing MYD88. Cotreatment of JH-X-119-01 with the BTK inhibitor ibrutinib resulted in synergistic killing effects in these systems. Importantly, the combination of JH-X-119-01 with Ibrutinib led to synergistic tumor cell killing in MYD88 mutated WM and ABC-DLBCL cells, and suppression of NF-ĸB activation. JH-X-119-01 shows synergistic tumor cell killing with ibrutinib in MYD88 mutated WM and ABC-DLBCL cells. In vivo PK studies revealed a favorable profile for JH-X-119-01 with a moderate half-life of 1.61 hours, a Cmax of 9.95 µM, and a low clearance of 18.84 mL/min/kg when dosed IV^[1].
参考文献

实验方案

技术信息

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

请登录您的专属账户